aim to enable chemists to assess endocrine toxicity early in the design process when they are first developing new molecules, long before chemicals reach market. They expect the protocol to be used in addition to assays aimed at evaluating other toxicity end points.
Coauthor Pete Myers, CEO and chief scientist for the nonprofit Environmental Health Sciences, explains that the computational and receptor-based assays recommended in the first three tiers all make assumptions about the mechanism of endocrine disruption, whereas live-animal assays recommended in tiers 4 and 5 are designed to catch endocrine-disruption activity via mechanisms that are not yet identified. "If you've made it through a series of assays, all of which turn up negative, and the material has potential economic value, you will be more willing to do the more intensive and expensive assays," he says.
Chemicals that test positive for endocrine disruption early on can either be set aside without investing any further time or money, or potentially redesigned to eliminate this characteristic. The authors point out that BPA and phthalates, had they gone through TiPED, would have been identified as endocrine disruptors in Tier 1, while atrazine, perchlorate, and perfluorinated compounds might have made it to Tier 3 or 4 before being identified. The protocol appears "to be an effective systematic, progressive and pragmatic way for chemists to determine the potential endocrine-disrupting activity of a new chemical they are designing," says Roger McFadden, senior scientist for consumer office goods retailer Staples, Inc. "Emerging domestic and international chemical regulations and a heightened consumer awareness about chemicals of concern in products is challenging businesses to take a more proactive and preemptive approach to supply chain management [and] materials selection at the product design stage," he explains.
Market research firm Pike Research predicts the market for green chemistry will grow dramatically, from $2.8 billion in 2011 to $98.5 billion in 2020.
2 The "clean little secret" that people in a wide variety of industries-including electronics, aerospace, cosmetics, agriculture, and energy-are increasingly recognizing is that green chemistry leads to good business decisions, says Paul Anastas, who directs Yale University's Center Lack of validation does not necessarily mean an assay is invalid. But it does mean results from the assay could be considered unreliable by regulatory agencies, depending on other factors. However, Myers says TiPED "isn't designed to inform regulation; it's designed to provide [individual] chemists the knowledge base to develop a new generation of materials that are inherently safer."
The authors envision that their protocol will change over time as new and improved assays are developed. "It's a living protocol that can evolve with the science," says coauthor Karen Peabody O'Brien, executive director of the nonprofit Advancing Green Chemistry. Additional information about the protocol is available at http://www.tipedinfo.com/.
Warner says he welcomes challenges to the protocol in the belief that they will eventually inspire the various factions to agree about what the right assays are. When that happens, the authors say that any business that follows the protocol can assure consumers, stock holders, and regulators that they made the best possible effort to ensure their new chemicals and products are not endocrine disruptors.
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